---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-111583"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2026-09-29T11:05:31+00:00"
generated_at: "2026-10-12T13:41:40.531584+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Iovance raises FY2026 revenue guidance to $410-$420M from $350-$370M on Amtagvi, Proleukin demand

## Summary
- FY2026 total revenue guidance raised to $410-$420M, up $55M (~15%) at the midpoint from the prior $350-$370M range; implies nearly 60% annual growth.
- Iovance most recently reported record Q2 2026 total product revenue of $99.3M, driven by strong U.S. demand for Amtagvi (lifileucel) and Proleukin.
- Authorized treatment center (ATC) network has grown to ~100 centers, with expansion to at least 110 ATCs expected by year-end 2026.
- Interim CEO Frederick Vogt cites current manufacturing schedule as giving strong visibility into Q3 and Q4 revenues, plus efficiencies accelerating progress toward profitability.
- Q3 2026 financial results expected in early November 2026; this update completes the guidance review announced with Q2 results.

## SEC filing metadata
- accession: 0001104659-26-111583
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2026-09-29T11:05:31+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465926111583/0001104659-26-111583-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465926111583/tm2626507d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-111583
- JSON: https://secwatch.observer/filing/0001104659-26-111583.json
- Plain text: https://secwatch.observer/filing/0001104659-26-111583.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.